According to Nova one advisor, the global Synthetic Biology market size was valued at USD 10,295.9 Million in 2022 and is predicted to hit USD 55,372.2 Million by 2030 with a registered CAGR of 19.7% during the forecast period 2022 to 2030.
Key Takeaways:
The presence of government and private funding to support research in vaccines and a strong synthetic biologic-based product pipeline in clinical trials are the key driving factors for the market. Synthetic biology processes provide crucial advantages for producing antigen and diagnostic reagents for disease identification, accelerating the speed of vaccine development, and improving overall vaccine performance and yield.
Furthermore, support from government agencies and the presence of several programs are likely to boost the market growth. For instance, in the U.S., COVID-19 vaccine R&D, manufacture, regulation, and purchase have been highly supported by collaboration between federal agencies, including the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH), DOD, FDA, and others (formerly OWS).
Other factors such as expanding demand in industries such as textiles and nutrition are also contributing to the market growth. Several optimal food production processes have been identified with the help of synthetic biology. In addition, synthetic biology is predicted to aid in the generation of higher agricultural yields and pest control development. It is expected to help in the production of better food yield and pest control management.
The COVID-19 pandemic is anticipated to positively impact market growth. Synthetic biology has been highlighted as a means to accelerate vaccine development by the National Institute of Health in the U.S. Therefore, synthetic biology labs and companies have been actively utilizing this technology to combat the COVID-19 pandemic. As a result, the usage of these technologies is projected to increase during the outbreak.
The growing demand for personalized medicine is expected to majorly drive market growth during the coming years. The use of engineered novel proteins for use as therapeutics has demonstrated synthetic biology in the medical segment. These proteins are designed with some modified protein structure to get the desirable properties required for the treatment. For instance, researchers are developing a therapeutic enzyme candidate that is GI-stable and can be given via oral route to treat Phenylketonuria (PKU).
On the other hand, synthetic biology has raised a few concerns regarding biosecurity and biosafety. Exposure to these products may cause unknown hazards to public health and the environment. To prevent such issues, countries of Europe, the Americas, and Asia have formulated policies to manage the application of synthetic biology techniques in basic & applied research.
Report Scope of the Synthetic Biology Market
Report Coverage |
Details |
Market Size |
USD 55,372.2 Million by 2030 |
Growth Rate |
CAGR of 19.7% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Technology, product, application, end-use and Region, |
Companies Mentioned |
Bota Biosciences Inc.; Codexis, Inc.; Creative Biogene; CREATIVE ENZYMES; Enbiotix, Inc.; Illumina, Inc.; Merck Kgaa (Sigma-Aldrich Co. LLC); New England Biolabs; Euro fins Scientific; Novozymes; Pareto Bio, Inc.; Scarab Genomics, LLC; Synthego; Synthetic Genomics Inc.; Thermo Fisher Scientific, Inc. |
Technology Insights
The PCR segment held the highest market share of 27.9% in 2021 and the trend is expected to continue throughout the forecast period. Polymerase Chain Reaction (PCR) has emerged as one of the key technologies for the detection and analysis of specific gene sequences. The real-time PCR assays provide high sensitivity and specificity, making it the go-to method for numerous genomic studies based on PCR. This technique is widely used in various areas such as forensic research, DNA cloning, molecular diagnostics, and genomics.
Genome editing technology, on the other hand, is anticipated to expand at a substantial CAGR during the projected period. The anticipated growth of gene-editing tools can be attributed to several advantages associated with synthetic and genetically modified organisms. The ability of gene editing techniques to develop products with desired traits has revolutionized various sectors, including human & animal healthcare and the agricultural sector.
Product Insights
Oligonucleotide/Oligo Pools and Synthetic DNA segment generated a revenue of USD 3,636.1 million in 2021. In several molecular and synthetic biology applications, oligonucleotides are considered the primary point. Increasing adoption of targeted NGS, mutagenesis experiments, DNA computing, and CRISPR gene editing are the major segment drivers for the same. For instance, OligoMix is an innovative and personalized product for genomics discoveries. It synthesizes numerous sequences of oligonucleotide in massive parallel. The cost for the same is lower than 0.8 cents per base.
On the other hand, the enzymes segment is anticipated to expand at a CAGR of 20.0% during the forecasted period. Enzymes are used as catalysts during biochemical reactions. The prospective application of enzymatic synthesis in delivering lengthier genes in a limited turnaround time is anticipated to boost market growth. However, the technology is still in the developing stage and has not yet been commercialized.
Application Insights
The healthcare segment dominated the market and is expected to expand at a CAGR of 20% throughout the forecast period. Diagnostic based on synthetic biology provides a highly specific, sensitive, real-time, and non-invasive process for detecting infectious agents, cancer cells, and therapeutics. Researchers employ rational engineering techniques to design novel bio-sensing systems that are dynamic and constituted of a processor, sensor, and reporter.
The segment is also propelled by an increase in neurological disorders such as multiple sclerosis. For instance, as of July 2022, the experts in synthetic biology from the University of Toronto Engineering are developing custom stem cells from the tissues of patients to treat diseases. Such research efforts are anticipated to supplement the segment growth.
End-use Insights
The biotechnology and pharmaceutical companies segment captured the highest revenue share of 52.1% in 2021. Synthetic biology has aided biotech and pharmaceutical companies in the development of new therapeutics for chronic diseases. For instance, Merck utilized synthetic biology techniques to generate Januvia (sitagliptin), a diabetes medication. Moreover, Novartis introduced Kymriah (Tisagenlecleucel) for the treatment of B-cell acute lymphoblastic leukemia.
Furthermore, the academic & government research institutes segment is expected to show steady growth during the forecast period. The R&D sector is considered to be capital-intensive owing to long development periods and approval cycles. R&D expenditure and funding have witnessed a steady increase during the years. According to an article published in September 2020, the R&D spending in the life sciences industry surged 22% from 2018 to 2019.
Regional Insights
North America dominated the regional market with a share of 42.3% in 2021. This major share can be attributed to increasing investment in private companies, favorable regulations, and government assistance. The U.S. majorly concentrates on research in the area of proteomics, drug screening & discovery, and genomics structure prediction, thereby propelling the growth of the synthetic biology market.
The Asia Pacific is estimated to be the fastest-growing region; the significant developments by rising investments in Asia Pacific countries, increasing partnerships & funding in the Chinese market, and increasing collaborations in the field of synthetic biology are among the factors anticipated to drive the growth of the synthetic biology market. Moreover, several Asian countries have recently established national institutes, state-sponsored research programs, and academia-industry collaborations to promote technological innovation for the advancement of synthetic biology.
Some of the prominent players in the Synthetic Biology Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Synthetic Biology market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders